Previous individual trials of alirocumab (a PCSK9 monoclonal antibody) showed significant low-density lipoprotein cholesterol reductions with overall treatment-emergent adverse event (TEAE) rates comparable with controls. This analysis evaluated safety data from 14 trials (4 phase 2 and 10 phase 3, 8 to 104 weeks; n [ 5, 234) , in 2 pools according to control (placebo/ezetimibe). Overall, 3,340 patients received alirocumab (4,029 patient-years' exposure), 1,276 received placebo, and 618 received ezetimibe. Incidence of deaths, serious TEAEs, discontinuations because of TEAEs, and overall TEAEs were similar between alirocumab and control groups. Alirocumab was associated with a higher incidence of local injection site reactions (7.4% vs 5.3% with placebo; 3.1% vs 2.3% with ezetimibe), pruritus (1.3% vs 0.4% placebo; 0.9% vs 0.5% ezetimibe), and upper respiratory tract infection signs and symptoms (2.1% vs 1.1% placebo; 1.3% vs 0.8% ezetimibe). Incidence of musculoskeletal, neurologic, neurocognitive, ophthalmologic, hepatic events, and TEAEs related to diabetes/diabetes complications was similar between alirocumab and control groups. In a prespecified analysis of phase 3 studies, adjudicated major adverse cardiovascular events (coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, and unstable angina requiring hospitalization) occurred in 1.8% alirocumab versus 2.6% placebo patients (hazard ratio 0.69, 95% confidence interval 0.43 to 1.11) and 2.8% alirocumab versus 1.5% ezetimibe patients (hazard ratio 1.4, 95% confidence interval 0.65 to 3.02). In conclusion, pooled safety data from 14 trials demonstrate that alirocumab is generally well tolerated with a favorable safety profile. Alirocumab, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9), was approved by the US Food and Drug Administration and the European Medicines Agency in 2015 for the treatment of adults with hypercholesterolemia who require additional lowering of low-density lipoprotein cholesterol (LDL-C). Alirocumab has been studied in phase 2 and 3 clinical trials with doubleblind treatment periods of 8 to 104 weeks. 1e13 The phase 3 (ODYSSEY) trials mainly recruited patients at high atherosclerotic cardiovascular disease risk, including those with heterozygous familial hypercholesterolemia, who had elevated LDL-C levels despite receiving maximally tolerated statin. In individual trials, alirocumab significantly reduced levels of LDL-C versus controls, and overall rates of treatment-emergent adverse events (TEAEs) and discontinuations were similar between alirocumab and control groups. The alirocumab clinical trial program was designed to provide extensive safety information. To better assess safety of alirocumab, this report presents pooled safety data from >5,000 patients who participated in 14 randomized, double-blind, controlled phase 2 and 3 trials.
Methods
Data from 14 trials (4 phase 2 and 10 phase 3) of 8 to 104 weeks' duration were analyzed ( Figure 1 ). 1e13 All study protocols were approved by the appropriate institutional review board, and all patients provided informed, written consent. Further details on the trials are given in the Supplementary Material. This analysis focuses on TEAEs, defined as events occurring from the first dose of study treatment to the last dose (plus 70 days to account for the prolonged effect of alirocumab). Adverse events (AEs) of special interest categories were defined based on potential theoretical risks for the new drug class and included local injection site reactions, general allergic, neurologic, neurocognitive, hepatic, ophthalmologic, diabetes related, and musculoskeletal events ( Supplementary Table 1 ). Cardiovascular events were adjudicated in the phase 3 trials. Laboratory values were also assessed. Statistical analyses compared incidence of AEs of interest and commonly occurring (not prespecified) AEs between alirocumab and either placebo or ezetimibe in pools according to control used. Further details on methods are given in the Supplementary Material. Figure 1 . Numbers of patients who received alirocumab, placebo, or ezetimibe from each study who were included in the pooled safety analysis. This analysis includes safety data from 4 phase 2 and 10 phase 2 trials. The figure indicates the trial names, patient population, background therapy, duration of double-blind treatment in weeks, and number of patients who received alirocumab, placebo, or ezetimibe and were included in the analysis. "*," Fixed doses of atorvastatin 20 or 40 mg were used in OPTIONS I and rosuvastatin 10 or 20 mg in OPTIONS II. Study references (clinicaltrials.gov identifiers): DFI111565 (NCT01288443), 2 DFI11566 (NCT01288469), 1 CL-1003 (NCT01266876), 3 DFI12361 (NCT01812707), 13 LONG TERM (NCT01507831), 8 HIGH FH (NCT01617655), 5 COMBO I (NCT01644175), 7 FH I (NCT01623115) þ FH II (NCT01709500), 9 COMBO II (NCT01644188), 6 OPTIONS I (NCT01730040), 10 OPTIONS II (NCT01730053), 12 MONO (NCT01644474), 4 and ALTERNATIVE (NCT01709513). 11 ALI 150 ¼ alirocumab 150 mg Q2W; ALI 75 ¼ alirocumab 75 mg Q2W; ALI 75/150 ¼ alirocumab 75 mg Q2W with dose increase to 150 mg Q2W at week 12 depending on week 8 LDL-C level; CV ¼ cardiovascular; EZE ¼ ezetimibe; HeFH ¼ heterozygous familial hypercholesterolemia; LDL-C ¼ low-density lipoprotein cholesterol;
Results
Safety data were available for 3,340 patients treated with alirocumab (representing 4,029 patient-years of alirocumab exposure), 1,276 treated with placebo, and 618 treated with ezetimibe ( Figure 1 ). Baseline characteristics were similar for alirocumab and control groups ( Table 1 ). All patients in phase 3 placebo-controlled studies and most in the ezetimibe-controlled studies were receiving maximally tolerated statin (Table 1) as per the study designs ( Figure 1 ). Baseline characteristics and LDL-C efficacy data from the individual trials are listed in Supplementary Tables 2 and 3. Overall rates of TEAEs, serious AEs, discontinuations, and deaths were similar between alirocumab and control groups in both pools ( Table 2) . Details of deaths are given in Supplementary Table 4 .
Local injection site reactions were reported by a significantly higher proportion of alirocumab-treated patients compared with placebo (7.4% vs 5.3%; hazard ratio [HR] 1.47, 95% confidence interval [CI] 1.11 to 1.95) and by a nonsignificantly higher proportion of alirocumab-treated patients versus ezetimibe (3.1% vs 2.3%; HR 1.49, 95% CI 0.78 to 2.86; Table 3 ). Few patients withdrew from the trials because of local injection site reactions (Table 3) , and no serious events were reported. Most local injection site reactions were graded as mild in severity and transient. Two events were graded as severe: 1 in an alirocumab-treated patient that resolved in 1 day without treatment and did not result in treatment discontinuation and 1 in a patient allocated to ezetimibe who reported a severe reaction from the placebo injection that required treatment and resulted in treatment discontinuation.
General allergic events were overall reported at similar rates with alirocumab versus control in both pools and few were reported as being serious (Table 3 ). Of the specific events that form this category ( Supplementary Table 5 ), a significantly higher incidence of pruritus was observed with alirocumab versus placebo (1.3% vs 0.4%; HR 3.15, 95% CI 1.22 to 8.09); pruritus was reported in 0.9% alirocumab versus 0.5% ezetimibe patients (HR 1.86, 95% CI 0.49 to 7.11). Other rarer, sporadic allergic AEs occurred, including hypersensitivity, eczema nummular, urticaria, and hypersensitivity vasculitis.
Neurologic events occurred at similar rates in alirocumab and control groups and few led to treatment discontinuation ( Table 3 ). Serious neurologic events reported with alirocumab were single occurrences, without evidence of a common underlying pathogenic mechanism. Incidence of neurocognitive events was low and similar between alirocumab and control groups ( Table 3 ). The most common neurocognitive events were memory loss and amnesia (both 0.5% of patients; Supplementary  Table 5 ). Ophthalmologic events occurred at similar rates in the alirocumab groups compared with controls ( Table 2) . Incidence of hepatic TEAEs, including single alanine aminotransferase (ALT) elevations, was similar between alirocumab versus controls ( Table 3 ). Single elevations of ALT and aspartate aminotransferase were observed in similar frequencies in alirocumab and control groups (Supplementary Table 6 ). There were 4 cases overall (2 with alirocumab and 2 with placebo) of combined elevations in ALT and bilirubin levels falling into Hy's law range (3 times upper limit of normal [ULN] and 2 times ULN, respectively); however, all these cases had alternative etiologies (e.g., hepatitis A or pre-existing liver disease). No cases of hemolytic anemia were reported. Levels of hemoglobin were similar between alirocumab and control groups and did not change over the course of any of the studies. There was no difference in incidence of musculoskeletal events between alirocumab and placebo, and fewer alirocumab-treated patients had musculoskeletal events overall versus ezetimibe in the ALTERNATIVE study (Table 3 ). There were no significant differences between groups in rates of specific musculoskeletal events, including myalgia ( Supplementary Table 5 ). Most musculoskeletal events were mild to moderate in severity, and severity was comparable between treatment groups. Elevated creatine kinase >3 or >10 times ULN was reported in a similar proportion of patients in alirocumab and control groups (Supplementary Table 6 ).
AEs related to diabetes were infrequent, with no difference between alirocumab and control groups ( Table 3 ). There were no differences in the change in fasting plasma glucose and glycated hemoglobin (HbA 1c ) over time between alirocumab and control groups, regardless of diabetes status at baseline ( Supplementary Figures 1 and 2 
online).
Major adverse cardiovascular events occurred in 1.8% alirocumab versus 2.6% placebo patients (HR 0.69, 95% CI 0.43 to 1.11) and in 2.8% alirocumab versus 1.5% ezetimibe patients (HR 1.40, 95% CI 0.65 to 3.02). Further details on cardiovascular events are given in Supplementary Table 7 .
Aside from local injection site reactions and pruritus, rates of other AEs were similar between alirocumab and control groups, including gastrointestinal AEs, such as diarrhea, nausea, and constipation ( Table 2 ; Supplementary  Table 8 ). An exception was the Medical Dictionary of Regulatory Activities higher level term "upper respiratory tract infections signs and symptoms" (including mainly oropharyngeal pain, rhinorrhea, and sneezing), which was reported at a statistically higher rate with alirocumab versus placebo (2.1% vs 1.1%; HR 1.87, 95% CI 1.04 to 3.38); the difference between alirocumab versus ezetimibe was not significant (1.3% vs 0.8%; HR 1.44, 95% CI 0.49 to 4.20; further details given in Supplementary Table 9 ). Among alirocumab-treated patients, there was no increased incidence of this event category for patients who had LDL-C values <25 mg/dl (1.3%) compared with those who did not have such LDL-C values (1.8%).
Discussion
This is the largest safety analysis of alirocumab in terms of patient numbers (3,340 treated with alirocumab) and exposure (4,029 patient-years). Most patients were observed for !52 weeks in double-blind studies, with 64.4% observed for up to 76 weeks. Overall rates of TEAEs, SAEs, premature discontinuations, and deaths were similar between alirocumab treatment and control groups (placebo and ezetimibe).
Rates of local injection site reactions occurred at a higher rate with alirocumab versus controls; most injection site reactions were transient, few led to discontinuation, and most were mild in severity. Local injection site reactions could represent local intolerability because of the device or the drug, the viscosity, volume, or other aspects of which may have contributed to symptoms, such as pain, stinging, and redness. Furthermore, as patients with persistently positive anti-drug antibodies have been shown to experience 1808
The American Journal of Cardiology (www.ajconline.org) a greater incidence of injection site reactions compared with patients without such antibodies, 14 an immune-based response is possible; however, the precise mechanism is unknown. Similarly, the precise mechanism for the increased rate of pruritus with alirocumab is unknown. Most patients were receiving concomitant statins at maximally tolerated dose. Safety events associated with statin treatment include muscle symptoms and increased incidence of diabetes. 15e17 Importantly, the addition of alirocumab treatment was not associated with any increase neither in musculoskeletal events (including myalgia or clinically meaningful changes in creatine kinase levels) nor in hepatic disorders, including single elevations in ALT, and no cases of confirmed Hy's law were observed. Incidence of AEs related to diabetes was similar between alirocumab and controls (including no clinically meaningful differences between mean HbA 1c and fasting plasma glucose levels between groups). Furthermore, alirocumab does not increase incidence of new-onset diabetes based on phase 3 data. 18 Although our analysis did not find any neurocognitive event differences between alirocumab and placebo/ezetimibe, a network meta-analysis of phase 2 and 3 trials with alirocumab and evolocumab did find the incidence of neurocognitive events to be increased (odds ratio 2.34, 95% CI 1.11 to 4.93, p ¼ 0.02), primarily because of their inclusion of the 2 large, long-term trials of both drugs. 8, 19, 20 However, this meta-analysis only included 2 alirocumab phase 3 studies (LONG TERM and COMBO I), whereas our pooled analysis includes 14 trials. Another recent meta-analysis of PCSK9 antibody trials did not provide any neurocognitive AE data. 21 Dedicated neurocognitive trials are planned to address this issue further.
Although the rate of the higher level term category "upper respiratory tract infection signs and symptoms" was Supplementary Table 5 .
† Number of patients with an event divided by total patient-years. z Ezetimibe-controlled pool data are for ALTERNATIVE only (n ¼ 126 alirocumab, 124 ezetimibe), due to the high rate of events in this study of patients with documented statin intolerance that would otherwise skew results if pooled with the other ezetimibe-controlled trials.
x Baseline diabetes defined based on medical history. significantly greater with alirocumab (2.1%) versus placebo (1.1%), this was considered to be a chance finding. We have no mechanistic basis for an increase in this AE category with alirocumab, and this finding was not related to low levels of LDL-C. This analysis reports the largest and longest safety data for a PCSK9 monoclonal antibody available to date. However, it was limited by the number of patients and the overall duration of the studies for examination of rare events (e.g., only 32 neurocognitive events were reported in the alirocumab group). Furthermore, none of the data included in this analysis were derived from a prospective clinical trial designed to determine the effect of alirocumab on cardiovascular events and safety. The ongoing 18,000-patient ODYSSEY OUTCOMES trial will provide sufficient statistical power to adequately determine the effect of alirocumab on major adverse cardiovascular events. 22 
